Overall mortality in our cohort was 14.0%; mortality was lowest in Luminal A and Luminal B breast cancer (12.6% and 13.4%, respectively), and higher in HER2-positive and triple-negative breast cancer (17.6% and 22.2%, respectively). Here, ERBB2 is linked to breast carcinoma.